Back

Moleculin to present Annamycin data at three September 2026 scientific venues

Verifying
  • Moleculin will present Annamycin data at three scientific venues in September 2026.
  • September 25 marks publication of the embargoed AACR pancreatic-cancer abstract.
  • MIRACLE remains Moleculin’s primary development focus for relapsed or refractory AML.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.